This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n8http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q71059682
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована в березні 1996 wetenschappelijk artikel scientific article published on 01 March 1996 article scientifique publié en 1996 artículu científicu espublizáu en marzu de 1996 im März 1996 veröffentlichter wissenschaftlicher Artikel bài báo khoa học
p:P577
wds:Q71059682-A65A391F-71B8-4C91-8BF6-F5AF174432A6
wdt:P577
1996-03-01T00:00:00Z
p:P407
wds:Q71059682-582773A9-D04B-4148-9BF2-8B1F262822E2
wdt:P407
wd:Q1860
p:P2093
wds:Q71059682-A2E53788-1B50-4AE6-81B0-C6AA6F245C13 wds:Q71059682-7B4EA6A2-C688-40CA-8CB9-1CB0A98DF813 wds:Q71059682-3D7FB00A-761B-4872-87EB-A654042A1808 wds:Q71059682-ED862081-C95B-4E9F-AABE-82022A028928 wds:Q71059682-D43C4133-0D00-4FBD-A6BA-26B1AA41DBEC wds:Q71059682-EE746FE7-A79E-4F49-AEDE-6C65D49C593D wds:Q71059682-2944AE57-C2CB-4FC2-BEC5-7655B61A37BB wds:Q71059682-353D725A-54AC-4D21-B3D5-FA2357BC86CB wds:Q71059682-052A9755-160F-472B-A9D6-F06A56C54DF1
wdt:P2093
G Bertelli M Guelfi P Bruzzi M Venturini O Garrone R Rosso M R Sertoli L Del Mastro S Pastorino
rdfs:label
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer
skos:prefLabel
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer
schema:name
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer
p:P1476
wds:Q71059682-B687CAE0-EFA2-467A-A2E0-88B2A3883019
wdt:P1476
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer
p:P304
wds:Q71059682-C99BA5E7-14CE-4B3C-9456-9C7557B42F73
wdt:P304
764-773
p:P31
wds:Q71059682-920EC55C-5D82-4BEC-8AED-A9833084E171
wdt:P31
wd:Q13442814
p:P921
wds:Q71059682-EDDF2C88-F945-4858-AD19-498EDC0FCE16 wds:Q71059682-42C6B015-6370-4694-986B-DCF267CE4319 wds:Q71059682-21CB5479-9B42-45AF-ABE8-F74A04444609
wdt:P921
wd:Q974135 wd:Q238512 wd:Q12859063
p:P698
wds:Q71059682-49760739-DF64-4567-AD8B-8D088FF6D744
wdtn:P698
n12:8622022
wdt:P698
8622022
p:P1433
wds:Q71059682-B6A40FFC-84B6-4455-82BA-1A0252487DA8
wdt:P1433
wd:Q400292
p:P433
wds:Q71059682-FE9FEE0B-3D05-4743-95B9-304482C88C93
p:P478
wds:Q71059682-35AA0367-0E71-41BA-A09B-067138FA92EC
wdt:P433
3
wdt:P478
14
p:P356
wds:Q71059682-AAB318C1-3736-45D2-A68D-F40368EE0A25
wdtn:P356
n8:JCO.1996.14.3.764
wdt:P356
10.1200/JCO.1996.14.3.764